Register Login

EVOMMUNE, INC. (EVMN)

(90% Positive) EVOMMUNE, INC. (EVMN) Announces Enrollment Update for patients Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot June 29, 2026, 12:33 p.m.

    📋 EVOMMUNE, INC. (EVMN) - Clinical Trial Update

    Filing Date: 2026-06-29

    Accepted: 2026-06-29 08:32:15

    Event Type: Clinical Trial Update

    Event Details:

    EVOMMUNE, INC. (EVMN) Announces Clinical Trial Update EVOMMUNE, INC. (EVMN) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: patients, engagement
    • Clinical Stage: Phase 1, Phase 1 trial
    • Collaboration: NYSE

    🔬 Clinical Development Pipeline (EVOMMUNE, INC.):

    Product Type Development Stage Therapeutic Area Source
    EVO756, Dose 2 Other Phase PHASE2 Migraine ClinicalTrials.gov
    Placebo Other Phase PHASE2 Migraine ClinicalTrials.gov
    EVO756 Other Phase PHASE2 Atoptic Dermatitis ClinicalTrials.gov
    EVO756, Dose 1 Other Phase PHASE2 Migraine ClinicalTrials.gov
    Oral EVO756 50 mg BID Other Phase PHASE2 Chronic Inducible Urticaria ClinicalTrials.gov
    Oral EVO756 300 mg QD Other Phase PHASE2 Chronic Inducible Urticaria ClinicalTrials.gov
    Placebo control Other Phase PHASE2 Atoptic Dermatitis ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: EVOMMUNE, INC.
    • Ticker Symbol: EVMN

Search

News categories